Benzinga | Jun 7, 2021 05:16AM EDT

Novo Nordisk CFO Said Expects Approval of Semaglutide for Weight Management Treatment in the EU in December; Said Wegovy Could Eat into Sales of its Existing Obesity Drug Saxenda in the U.S.

-Reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/risk-patient-overlap-between-wegovy-saxenda-obesity-drugs-novo-says-2021-06-07/